Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Eva Barragán(Hospital Universitari i Politècnic La Fe), Pau Montesinos(Instituto de Salud Carlos III), Pedro Sánchez‐Godoy(Hospital Universitario Severo Ochoa), María L. Amador(Sidney Kimmel Comprehensive Cancer Center), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Óscar Fuster(Hospital Universitari i Politècnic La Fe), B. Löwenberg(Erasmus MC), María José Larráyoz(Navarre Institute of Health Research), Edo Vellenga(University Medical Center Groningen), Mireia Camós(Hospital Sant Joan de Déu Barcelona), Marcos González(Complejo Hospitalario de Salamanca), Carmen Chillón, Rosa Ayala(Hospital Universitario 12 De Octubre), José González‐Campos(Hospital Universitario Virgen del Rocío), María Teresa Gómez‐Casares(Universidad de Las Palmas de Gran Canaria), Dolors Colomer(Hospital Clínic de Barcelona), F. Manso(Hospital General Universitario de Albacete), José Román‐Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Marı́a José Calasanz(Navarre Institute of Health Research)
Cited by 65
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k